OSPREY Analysis Shows Survival Benefit for OncoSil Patients
Filed with ASX · · 3 pages · English
• First interim analysis of the OSPREY registry of 64 unresectable LAPC patients treated with the OncoSil™ device and gemcitabine-based chemotherapy in routine clinical practice across 19 centres in Europe • In first-line patients (75% of all patients), median Overall Survival was 20.6 months from diagnosis for those implanted with OncoSil™ at £4 months from starting chemotherapy, and 22.0 months
Earlier from OncoSil Medical
- Response to ASX Aware Letter
- Positive Preliminary Results from PANCOSIL Phase 1-2 Study
- Appendix 4E and Annual Report
- Completion of Recruitment in TRIPP-FFX Clinical Trial
- Completion of Recruitment in PANCOSIL Study
Later from OncoSil Medical
- OncoSil receives $1.84m R&D tax incentive
- Trading Halt
- Quarterly Activities/Appendix 4C Cash Flow Report
- $8.0 million Capital Raise for Ongoing Commercial Expansion
- Prospectus
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical